Real-world evidence in the treatment of ovarian cancer

Annals of Oncology

Volumn 28, Issue , 2017, Pages viii61-viii65

  Eisenhauer, Elizabeth A ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Ovarian cancer; Population outcomes; Real world evidence

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER SURGERY; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; EUROPE; HUMAN; MORTALITY RATE; NORTH AMERICA; OVARY CANCER; PRIORITY JOURNAL; SYSTEMIC THERAPY; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; EVIDENCE BASED PRACTICE; FEMALE; MORTALITY; NEOADJUVANT THERAPY; OVARY TUMOR; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CHEMOTHERAPY, ADJUVANT; EVIDENCE-BASED PRACTICE; FEMALE; HUMANS; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85039545911     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx443     Document Type: Article

References (13)

1. Booth CM, Siemens DR, Li G et al. Perioperative chemotherapy for muscle-invasive bladder cancer: a population-based outcomes study. Cancer 2014; 120: 1630-1638
2. Booth CM, Tannock I. Randomised controlled trials and populationbased observational research: partners in the evolution of medical evidence. Br J Cancer 2014; 110: 551-555
3. Vergote I, Tropé CG, Amant F et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363: 943-953
4. Kehoe S, Hook J, Nankivell M et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015; 386: 249-257
5. Rosen B, Laframboise S, Ferguson S et al. The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer. Gynecol Oncol 2014; 134: 462-467
6. Wright AA, Bohlke K, Armstrong DK et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016; 34: 3460-3473
7. Rauh-Hain JA, Melamed A, Wright A et al. Overall survival following neoadjuvant chemotherapy vs primary cytoreductive surgery in women with epithelial ovarian cancer: analysis of the National Cancer Database. JAMA Oncol 2017; 3: 76-82
8. Wright AA, Cronin A, Milne DE et al. Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer. J Clin Oncol 2015; 33: 2841-2847
9. Beral V, Doll R, Hermon C et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371: 303-314
10. Yang HP1, Anderson WF, Rosenberg PS et al. Ovarian cancer incidence trends in relation to changing patterns of menopausal hormone therapy use in the United States. J Clin Oncol 2013; 31(17): 2146-2151
11. https://seer.cancer.gov/statfacts/html/ovary.html (11 September 2017, date last accessed)
12. Trétarre B, Molinié F, Woronoff AS et al. Ovarian cancer in France: trends in incidence, mortality and survival, 1980-2012. Gynecol Oncol 2015; 139(2): 324-329
13. Malvezzi M, 2, Carioli G, Rodriguez T et al. Global trends and predictions in ovarian cancer mortality. Ann Oncol 2016; 27: 2017-2025